WO2010099219A3 - Designer ligands of tgf-beta superfamily - Google Patents
Designer ligands of tgf-beta superfamily Download PDFInfo
- Publication number
- WO2010099219A3 WO2010099219A3 PCT/US2010/025260 US2010025260W WO2010099219A3 WO 2010099219 A3 WO2010099219 A3 WO 2010099219A3 US 2010025260 W US2010025260 W US 2010025260W WO 2010099219 A3 WO2010099219 A3 WO 2010099219A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tgf
- beta superfamily
- designer ligands
- designer
- ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10746779.7A EP2401293B1 (en) | 2009-02-24 | 2010-02-24 | Designer ligands of tgf-beta superfamily |
CA2752647A CA2752647A1 (en) | 2009-02-24 | 2010-02-24 | Designer ligands of tgf-beta superfamily |
JP2011551315A JP5841845B2 (en) | 2009-02-24 | 2010-02-24 | Designer ligands of the TGF-β superfamily |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15506609P | 2009-02-24 | 2009-02-24 | |
US61/155,066 | 2009-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010099219A2 WO2010099219A2 (en) | 2010-09-02 |
WO2010099219A3 true WO2010099219A3 (en) | 2011-01-06 |
Family
ID=42666199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/025260 WO2010099219A2 (en) | 2009-02-24 | 2010-02-24 | Designer ligands of tgf-beta superfamily |
Country Status (6)
Country | Link |
---|---|
US (2) | US8952130B2 (en) |
EP (1) | EP2401293B1 (en) |
JP (1) | JP5841845B2 (en) |
KR (1) | KR101558642B1 (en) |
CA (1) | CA2752647A1 (en) |
WO (1) | WO2010099219A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101767860B1 (en) | 2010-08-20 | 2017-08-14 | 와이어쓰 엘엘씨 | Designer osteogenic proteins |
US9688735B2 (en) * | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR101993714B1 (en) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | Compositions and methods of use in treating metabolic disorders |
EP4140497A1 (en) | 2013-04-08 | 2023-03-01 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
WO2014201143A1 (en) * | 2013-06-11 | 2014-12-18 | President And Fellows Of Harvard College | Methods and compositions for increasing neurogenesis and angiogenesis |
US20160287667A1 (en) * | 2013-11-08 | 2016-10-06 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
BR112017007962A2 (en) * | 2014-10-24 | 2018-01-23 | Koninklijke Philips Nv | method implemented by computer, device, storage media, computer program, kit, and kit use |
AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
US10307480B2 (en) | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3240563B1 (en) | 2014-12-29 | 2020-12-09 | Bioventus LLC | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
WO2017015622A2 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc | Gdf11 binding proteins and uses thereof |
PT3350220T (en) | 2015-09-15 | 2021-08-06 | Scholar Rock Inc | Anti-pro/latent-myostatin antibodies and uses thereof |
CN109310742B (en) | 2016-01-06 | 2022-12-02 | 哈佛学院校长同事会 | Treatment with GDF11 prevents weight gain, increases glucose tolerance and reduces fatty liver |
SG11201805709RA (en) | 2016-01-08 | 2018-07-30 | Scholar Rock Inc | Anti-pro/latent myostatin antibodies and methods of use thereof |
TWI815793B (en) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | Binding proteins and methods of use thereof |
WO2017209523A1 (en) * | 2016-05-31 | 2017-12-07 | Mogam Institute For Biomedical Research | Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof |
EP3464337A4 (en) * | 2016-05-31 | 2019-12-18 | Mogam Institute for Biomedical Research | Ab6 family designer ligands of tgf-beta superfamily |
KR20190005239A (en) * | 2016-05-31 | 2019-01-15 | 재단법인 목암생명과학연구소 | Composition for the treatment of liver disease, including the AB6 family designer ligand of the TGF-beta super family and use thereof |
KR20230169484A (en) | 2016-06-13 | 2023-12-15 | 스칼러 락, 인크. | Use of myostatin inhibitors and combination therapies |
WO2018122794A1 (en) | 2016-12-30 | 2018-07-05 | Biogend Therapeutics Co., Ltd. | Recombinant polypeptides and nucleic acid molecules, compositions, and methods of making and uses thereof |
US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
WO2018148649A1 (en) * | 2017-02-10 | 2018-08-16 | The Institute For Cancer Research D/B/A | Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance |
AU2018228435A1 (en) | 2017-03-02 | 2019-10-03 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
WO2020101366A1 (en) * | 2018-11-15 | 2020-05-22 | joint Center for Biosciences | Activin/bmp7 chimeras: super-active sab704 and sab715, and their respective noggin-sensitized variants, nab704 and nab715; and nab204 |
WO2021081258A1 (en) | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | TGF-β POLYPEPTIDES |
EP4247431A1 (en) * | 2020-11-23 | 2023-09-27 | Cue Biopharma, Inc. | Tgf-beta polypeptides |
US11945856B2 (en) | 2022-01-28 | 2024-04-02 | 35Pharma Inc. | Activin receptor type IIB variants and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020591A2 (en) * | 1998-10-07 | 2000-04-13 | Stryker Corporation | Tgf-beta superfamily mutant members, including morphogenic proteins |
WO2005113585A2 (en) * | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
WO2006047728A2 (en) * | 2004-10-27 | 2006-05-04 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Bmp gene and fusion protein |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
ZA874681B (en) * | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
US5106748A (en) * | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
US5108922A (en) * | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
US4877864A (en) * | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
US5155058A (en) * | 1986-11-07 | 1992-10-13 | Canon Kabushiki Kaisha | Method of making semiconductor memory device |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
DK0448704T3 (en) | 1989-10-17 | 1999-04-06 | Stryker Corp | Osteogenic devices |
WO1992007004A1 (en) | 1990-10-18 | 1992-04-30 | Creative Biomolecules, Inc. | Osteogenic protein |
US5677196A (en) * | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US6333168B1 (en) * | 1993-05-20 | 2001-12-25 | The Trustees Of Columbia University In The City Of New York | Cloning, expression and uses of dorsalin-1 |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
DE69840361D1 (en) | 1997-07-30 | 2009-01-29 | Univ Emory | NEW BONE MINERALIZATION PROTEINS, DNA, VECTORS, EXPRESSION SYSTEMS |
US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
-
2010
- 2010-02-24 CA CA2752647A patent/CA2752647A1/en active Pending
- 2010-02-24 EP EP10746779.7A patent/EP2401293B1/en active Active
- 2010-02-24 JP JP2011551315A patent/JP5841845B2/en active Active
- 2010-02-24 US US12/712,069 patent/US8952130B2/en active Active
- 2010-02-24 KR KR1020117021911A patent/KR101558642B1/en active IP Right Grant
- 2010-02-24 WO PCT/US2010/025260 patent/WO2010099219A2/en active Application Filing
-
2014
- 2014-12-30 US US14/586,573 patent/US20150239950A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020591A2 (en) * | 1998-10-07 | 2000-04-13 | Stryker Corporation | Tgf-beta superfamily mutant members, including morphogenic proteins |
WO2005113585A2 (en) * | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
WO2006047728A2 (en) * | 2004-10-27 | 2006-05-04 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Bmp gene and fusion protein |
Non-Patent Citations (2)
Title |
---|
KORUPOLU ET AL.: "Activin A/Bone Morphogenetic Protein (BMP) Chimeras Exhibit BMP-like Activity and Antagonize Activin and Myostatin", J. BIOLOGICAL CHEMISTRY, vol. 283, no. 7, 15 February 2008 (2008-02-15), pages 3782 - 3790, XP008150979 * |
See also references of EP2401293A4 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010099219A2 (en) | 2010-09-02 |
JP2012518420A (en) | 2012-08-16 |
CA2752647A1 (en) | 2010-09-02 |
EP2401293A4 (en) | 2012-07-18 |
EP2401293A2 (en) | 2012-01-04 |
US20100221777A1 (en) | 2010-09-02 |
JP5841845B2 (en) | 2016-01-13 |
US8952130B2 (en) | 2015-02-10 |
US20150239950A1 (en) | 2015-08-27 |
KR101558642B1 (en) | 2015-10-12 |
KR20110121642A (en) | 2011-11-07 |
EP2401293B1 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010099219A3 (en) | Designer ligands of tgf-beta superfamily | |
WO2011153276A3 (en) | Stable, functional chimeric cellobiohydrolase class i enzymes | |
WO2010118058A3 (en) | Polypeptides having cellulase activity | |
WO2012103300A3 (en) | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same | |
WO2013076259A3 (en) | Polypeptides having lysozyme activity and polynucleotides encoding same | |
WO2011035027A3 (en) | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same | |
WO2011005867A8 (en) | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same | |
WO2013019827A3 (en) | Polypeptides having xylanase activity and polynucleotides encoding same | |
WO2012146171A9 (en) | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same | |
WO2015040159A3 (en) | Polypeptides having mannanase activity and polynucleotides encoding same | |
EP2735611A3 (en) | Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same | |
MX2012006096A (en) | Polypeptides having glucoamylase activity and polynucleotides encoding same. | |
WO2007109441A3 (en) | Polypeptides having endoglucanase activity and polynucleotides encoding same | |
WO2010120514A3 (en) | Antigen-binding proteins comprising recombinant protein scaffolds | |
WO2007115201A3 (en) | Polypeptides having endoglucanase activity and polynucleotides encoding same | |
WO2010059413A3 (en) | Polypeptides having amylolytic enhancing activity and polynucleotides encoding same | |
WO2009079210A3 (en) | Polypeptides having xylanase activity and polynucleotides encoding same | |
MX337919B (en) | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same. | |
WO2009105141A3 (en) | Polypeptides having endoglucanase activity and polynucleotides encoding same | |
MX337913B (en) | Polypeptides having cellobiohydrolase activity and polynucleotides encoding same. | |
WO2013057141A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
WO2013057143A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
WO2010088463A3 (en) | Polypeptides having expansin activity and polynucleotides encoding same | |
WO2013074956A3 (en) | Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and polynucleotides encoding same | |
WO2012175708A3 (en) | Polypeptides having protease activity and polynucleotides encoding same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10746779 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010746779 Country of ref document: EP Ref document number: 2752647 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011551315 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117021911 Country of ref document: KR Kind code of ref document: A |